title: The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants.
abstract: OBJECTIVE
  Limited evidence suggests that selective serotonin reuptake inhibitor (SSRI) antidepressants can hinder platelet aggregation and can increase the risk of hemorrhage. Because antenatal depression is common and is often treated with antidepressants, we sought to determine if exposure to SSRI antidepressants in late pregnancy is associated with an increased risk of postpartum hemorrhage compared with non-SSRI antidepressants.
  
  
  METHODS
  This was a population-based nested case-control study of women aged 16 to 45 years in Ontario, Canada, who received government-funded prescription coverage within 2 years before delivery. We identified case patients with postpartum hemorrhage and matched controls (1:10) without postpartum hemorrhage from the same cohort. Controls were matched to cases on age, mode of delivery, parity, and calendar time. We linked prescription claims data to hospital and physician records for the study period (January 1999 to March 2005). Exclusion criteria included drugs and medical conditions that predispose to hemorrhage, and receipt of multiple antidepressants in the 6 months preceding delivery. Antidepressant drug exposure was classified as SSRI or other agents within 90 days before delivery.
  
  
  RESULTS
  There were 2460 postpartum hemorrhage cases and 23,943 matched controls. The adjusted odds ratio for the association between postpartum hemorrhage and exposure to SSRIs within 90 days before index date was 1.30 (95% confidence interval, 0.98-1.72) as compared with 1.12 (95% confidence interval, 0.62-2.01) for non-SSRIs.
  
  
  CONCLUSIONS
  Selective serotonin reuptake inhibitors confer no disproportionate risk of postpartum hemorrhage at the time of delivery compared with non-SSRI antidepressants. This information may help guide decisions regarding pharmacotherapy for depression during pregnancy.
authors.affiliation: Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Ontario, Canada.
authors.forename: Erin
authors.initials: E
authors.lastname: Salkeld
authors.forename: Lorraine E
authors.initials: LE
authors.lastname: Ferris
authors.forename: David N
authors.initials: DN
authors.lastname: Juurlink
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D016303:Clinical Pharmacy Information Systems / Q000706:statistics & numerical data; D036861:Delivery, Obstetric / Q000706:statistics & numerical data; D017723:Drug Utilization Review / Q000706:statistics & numerical data; D005260:Female; D005865:Gestational Age; D006801:Humans; D007345:Insurance Claim Review / Q000706:statistics & numerical data; D016015:Logistic Models; D015999:Multivariate Analysis; D007744:Obstetric Labor Complications / Q000139:chemically induced; D009864:Ontario / Q000453:epidemiology; D006473:Postpartum Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced; D011272:Pregnancy, Multiple / Q000706:statistics & numerical data; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors